Telik
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Telik sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Telik: 21 sponsored US clinical trials, none currently recruiting.
Telik sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 4 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small-Cell Lung Carcinoma, with 1 trials.
Top-decile sponsor footprint
Telik ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
21 total, page 1 of 1
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
NCT01422486
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
NCT01459159
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
NCT01148108
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01062152
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia
NCT00909584
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
NCT00701870
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
NCT00700206
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
NCT00350948
Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
NCT00280631
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00102973
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00088556
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00077883
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
NCT00057720
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00052065
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
NCT00051948
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
NCT00047801
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
NCT00040638
Phase 2 Study of TLK286 in Metastatic Breast Cancer
NCT00035841
Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
NCT00035867
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
NCT00038428
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00080340
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 9 |
| Phase 3 | 4 |
Therapeutic Areas
How the Telik early-phase archive is shaped
21 indexed studies, none listed as recruiting (0% open); 16 completed (76%).
Phase mix: 4 late (III/IV) vs 17 early (I/II) (early-phase heavy).
Top condition: Non-Small-Cell Lung Carcinoma (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Telik: archived-pipeline peers nationwide
Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Telik sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 archived trials
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Telik page
21 registered trials is a research-attention snapshot, not an endorsement of Telik or any single study.
- None of Telik's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Non-Small-Cell Lung Carcinoma is the condition Telik studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small-Cell Lung Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Telik pipeline card: 21 registered trials from official public datasets.Report a data error.